Carsten Nieder1,2, Bård Mannsåker3, Rosalba Yobuta3. 1. Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway; carsten.nieder@nlsh.no. 2. Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway. 3. Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway.
Abstract
BACKGROUND/AIM: The aim of this study was to analyze the survival predictions obtained from a recent graded prognostic model developed and validated in Japan. PATIENTS AND METHODS: This was a retrospective single-institution analysis of 249 patients, managed with whole-brain radiotherapy for brain metastases. The sum of scores was calculated as in the Japanese study. The following parameters were included: number of brain metastases, volume of the largest lesion, sex, Karnofsky performance status, primary cancer type, control of primary cancer, and presence of extra-cerebral metastases. RESULTS: Median overall survival was 3.0 months (95% CI= 2.6-3.4 months). The median sum of scores was 12, range=0-29. Statistically significant differences were observed between all prognostic strata. CONCLUSION: The graded prognostic model is also applicable to patients treated with whole-brain rather than stereotactic radiotherapy. Copyright
BACKGROUND/AIM: The aim of this study was to analyze the survival predictions obtained from a recent graded prognostic model developed and validated in Japan. PATIENTS AND METHODS: This was a retrospective single-institution analysis of 249 patients, managed with whole-brain radiotherapy for brain metastases. The sum of scores was calculated as in the Japanese study. The following parameters were included: number of brain metastases, volume of the largest lesion, sex, Karnofsky performance status, primary cancer type, control of primary cancer, and presence of extra-cerebral metastases. RESULTS: Median overall survival was 3.0 months (95% CI= 2.6-3.4 months). The median sum of scores was 12, range=0-29. Statistically significant differences were observed between all prognostic strata. CONCLUSION: The graded prognostic model is also applicable to patients treated with whole-brain rather than stereotactic radiotherapy. Copyright
Authors: Paul W Sperduto; Brian J Deegan; Jing Li; Krishan R Jethwa; Paul D Brown; Natalie Lockney; Kathryn Beal; Nitesh G Rana; Albert Attia; Chia-Lin Tseng; Arjun Sahgal; Ryan Shanley; William A Sperduto; Emil Lou; Amir Zahra; John M Buatti; James B Yu; Veronica Chiang; Jason K Molitoris; Laura Masucci; David Roberge; Diana D Shi; Helen A Shih; Adam Olson; John P Kirkpatrick; Steve Braunstein; Penny Sneed; Minesh P Mehta Journal: Neuro Oncol Date: 2018-11-12 Impact factor: 12.300
Authors: José Lorenzoni; Daniel Devriendt; Nicolas Massager; Phillippe David; Salvador Ruíz; Bruno Vanderlinden; Paul Van Houtte; Jacques Brotchi; Marc Levivier Journal: Int J Radiat Oncol Biol Phys Date: 2004-09-01 Impact factor: 7.038
Authors: John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang Journal: Nat Rev Clin Oncol Date: 2020-02-20 Impact factor: 66.675
Authors: Paul W Sperduto; T Jonathan Yang; Kathryn Beal; Hubert Pan; Paul D Brown; Ananta Bangdiwala; Ryan Shanley; Norman Yeh; Laurie E Gaspar; Steve Braunstein; Penny Sneed; John Boyle; John P Kirkpatrick; Kimberley S Mak; Helen A Shih; Alex Engelman; David Roberge; Nils D Arvold; Brian Alexander; Mark M Awad; Joseph Contessa; Veronica Chiang; John Hardie; Daniel Ma; Emil Lou; William Sperduto; Minesh P Mehta Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777